Gerresheimer AG Lowers 2026 Outlook and Forecasts Negative Free Cash Flow
Shares of Gerresheimer AG (ticker GXIG) fell on Monday, trading down about 0.62%, after the company announced a downgrade to its 2026 financial guidance. The German pharmaceutical packaging manufacturer now expects 2026 revenue, before any merger‑and‑acquisition activity or refinancing, to fall in the lower half of its previously indicated €2.3 billion to €2.4 billion range. Consequently, the adjusted EBITDA margin outlook has been trimmed to approximately 17 %‑18 %, compared with the earlier 18 %‑19 % band. Free cash flow is projected to be negative, ranging between €‑50 million and €‑100 million, a reversal from the prior expectation of modestly positive cash generation.
The downgrade was attributed to project delays on the part of customers and operational challenges, notably difficulties associated with production ramp‑ups. Despite these setbacks, Gerresheimer confirmed that the sale process for its Centor business remains on track and is still expected to close by the end of fiscal year 2026. The company also reiterated its plan to complete a comprehensive debt refinancing before that same deadline.
Key figures
- Revised 2026 revenue guidance: lower half of €2.3‑€2.4 billion.
- Adjusted EBITDA margin: now 17 %‑18 % (previously 18 %‑19 %).
- Free cash flow: expected between –€50 million and –€100 million (previously modestly positive).
- Stock reaction: down ~0.62% on the news.
- Centor sale and debt refinancing targeted for FY‑2026 completion.